Banque Pictet & Cie Sa Seagen Inc. Transaction History

Banque Pictet & Cie Sa

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	SELL	$187.64 - $206.25 $7.31 Million - $8.04 Million	-38,971 Reduced 93.54%	2,691 $517,000
Q1 2023 May 01, 2023	SELL	$127.59 - $203.08 $2.78 Million - $4.43 Million	-21,816 Reduced 34.37%	41,662 $8.44 Million
Q4 2022 Feb 06, 2023	BUY	$117.37 - $139.17 $1.45 Million - $1.72 Million	12,386 Added 24.24%	63,478 $0
Q3 2022 Nov 10, 2022	BUY	$135.27 - $180.11 $4.19 Million - $5.58 Million	30,966 Added 153.86%	51,092 $6.99 Billion
Q2 2022 Aug 08, 2022	SELL	$108.81 - $179.33 $210,873 - $347,541	-1,938 Reduced 8.78%	20,126 $3.56 Million

Q1 2022 May 04, 2022	SELL	$119.61 - $157.85 $611,087 - $806,455	-5,109 Reduced 18.8%	22,064 $3.18 Million
Q4 2021 Feb 02, 2022	BUY	$142.57 - $190.86 $3.87 Million - $5.19 Million	27,173 New	27,173 $4.2 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.